Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


TCT 2019: BD, VIVA Data Show Lower Paclitaxel Mortality Risk

Executive Summary

BD said an independent Lutonix review found no significant link to deaths, while further meta-analysis from trade group VIVA showed a decline in the risk.  Both studies were unveiled at the Transcatheter Cardiovascular Therapeutics (TCT) conference in San Francisco.

You may also be interested in...

VIVA 2019: 4-Year Data Shows Success For Medtronic’s In.Pact Admiral DCB

An ongoing trial of Medtronic’s In.Pact Admiral paclitaxel-coated balloon found a four-year survival rate in line with what would be expected for the patient population and a relatively low rate of complications.

German Patient Data Shows No Paclitaxel Mortality Risk

Newer Data Fades Paclitaxel Risk, Physician Group Says

A meta-analysis that seemed to show an increased mortality risk tied to paclitaxel-coated balloons and stents sent shockwaves through the device industry last year. But a more complete data review funded by nonprofit group VIVA Physicians may show that the issue has been overestimated.

Related Content


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts